https://orcid.org/0000-0002-9045-6495
Key points
Belantamab mafodotin showed ORR 45%, PFS 3.8 months, and OS 17.2 months in relapsed/refractory multiple myeloma in the real-world setting.
The ORR was 29% in heavily pre-treated patients who had received prior BCMA targeted therapy.
Abstract
Belantamab mafodotin is an antibody drug conjugate targeting B-cell maturation antigen (BCMA) for treatment of multiple myeloma. To evaluate the efficacy and safety of belantamab mafodotin in a real-world setting in the US, we assessed all patients treated with commercial belantamab mafodotin at Memorial Sloan Kettering Cancer Center between 2020 and 2023. Ninety-four patients were identified; 57 had high-risk cytogenetics, 77 were triple class refractory, the median prior lines of therapy was 6, and 18 patients had received prior BCMA targeted treatment. The overall response rate (ORR) was 43%, and 21% achieved a very good partial response (VGPR) or better. The median progression free survival (PFS) was 3.8 months, median overall survival (OS) 17.2 months, and median duration of response 10.5 months. In patients with prior BCMA exposure (median prior lines of therapy=9), the ORR was 29%, the PFS 2 months, and OS 20.4 months. Sixty-one patients (65%) had any grade ocular toxicity, 15 patients had grade 3 or more keratopathy. All keratopathy was reversible and had resolved or reduced to grade 1 by the end of follow up. Most patients could continue on a reduced dose or with longer dose interval while maintaining the clinical response. Eighteen patients had one or more infections, most were grade 1/2. In summary, belantamab mafodotin showed significant response rates overall and in patients with prior BCMA exposure. The ocular toxicity was similar to previous reports and the risk of serious infections was low in this cohort of heavily pre-treated multiple myeloma patients.
